Patents by Inventor Rajeeva Singh
Rajeeva Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230105468Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: ApplicationFiled: October 12, 2022Publication date: April 6, 2023Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. CHARI
-
Patent number: 11498979Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: September 24, 2020Date of Patent: November 15, 2022Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Patent number: 11046762Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: October 14, 2019Date of Patent: June 29, 2021Assignee: IMMUNOGEN, INC.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20210163625Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: ApplicationFiled: September 24, 2020Publication date: June 3, 2021Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. CHARI
-
Patent number: 10815309Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: February 1, 2019Date of Patent: October 27, 2020Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Publication number: 20200148764Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: October 14, 2019Publication date: May 14, 2020Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Patent number: 10494431Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: March 5, 2018Date of Patent: December 3, 2019Assignee: IMMUNOGEN, INC.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20190263935Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: February 1, 2019Publication date: August 29, 2019Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Patent number: 10364294Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: GrantFiled: August 15, 2017Date of Patent: July 30, 2019Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
-
Patent number: 10233257Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: September 1, 2017Date of Patent: March 19, 2019Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20180291100Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: March 5, 2018Publication date: October 11, 2018Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20180079828Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: September 1, 2017Publication date: March 22, 2018Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V.J. Chari
-
Publication number: 20180037659Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: ApplicationFiled: August 15, 2017Publication date: February 8, 2018Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
-
Patent number: 9868791Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: GrantFiled: April 13, 2016Date of Patent: January 16, 2018Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
-
Patent number: 9771432Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: May 27, 2016Date of Patent: September 26, 2017Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20170157264Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: October 14, 2016Publication date: June 8, 2017Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20170002096Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: May 27, 2016Publication date: January 5, 2017Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. J. CHARI
-
Publication number: 20170002393Abstract: Compositions and methods for minimizing antibody disulfide bond reduction are described. In one aspect, a composition is provided for culturing mammalian host cells to express an antibody including an anti-reduction agent that minimizes reduction of a disulfide bond in the antibody or fragment thereof. In some other aspects, methods for minimizing disulfide bond reduction; increasing production of an antibody or fragment thereof with intact native disulfide bonds; increasing a ratio of non-reduced to reduced antibody or fragment thereof; producing a therapeutic antibody or fragment thereof by adding a sufficient amount of an anti-reduction agent to a cell culture media, pre-harvest cell culture fluid, or harvest cell culture fluid are described. In another aspect, minimizing disulfide bond reduction in an antibody or fragment thereof culturing the host cell in a concentration of at least about 20% O2 is described.Type: ApplicationFiled: December 3, 2014Publication date: January 5, 2017Applicant: IMMUNOGEN, INC.Inventors: RAJEEVA SINGH, NATHAN FISHKIN, SETH KITCHENER, DEBORAH MESHULAM
-
Patent number: 9498541Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: May 15, 2015Date of Patent: November 22, 2016Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20160324980Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: ApplicationFiled: April 13, 2016Publication date: November 10, 2016Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva SINGH